11494 Sorrento Valley Road, Suite M San Diego, CA 92121

510(K) Summary

In accordance with the Safe Medical Devices Act of 1990, a 510(K) summary is provided as outlined in 21 CFR 807.92.

C.	. L.	:	44.	~ ==
Su	ını	mı	ш	er

Name:

Alfa Scientific Designs, Inc.

Address: 11494 Sorrento Valley Road, Suite M

San Diego, CA 92121 Telephone: (858) 350-9798 Fax: (858) 350-9709

Email: asdi@worldnet.att.net

Device name

Trade Name:

Instant-View ™ Methamphetamine (Meth1000) Urine

Test (Dip Strip)

Common Name: Methamphetamine Test

Classification Name: 21 CFR 862.3610, Class II

Device being modified

Instant-ViewTM device. marketed The legally Methamphetamine Urine Test (Dip Strip). K994406, has been modified on the cutoff level, from 500ng/ml to 1000ng/ml. The modification did not alter the intended use of the modified device, the fundamental scientific technology and the Clinical Considerations.

Device description

This test is a one-step lateral flow chromatographic immunoassay.

Intended use

The Instant-View ™ Methamphetamine (Meth1000) Urine Test (Dip Strip) is a qualitative immunoassay device intended to detect methamphetamine in human urine at a cutoff level of 1000 ng/ml. It is intended for health care professional use only.

Summary of the similarities to the modified device

• Intended Use:

Both devices are intended to detect methamphetamine in human urine.

• Technological Characteristics: Both devices are one step, qualitative, competitive binding immunoassay test, utilizing the basic

immunochemical sandwich assay principle of recognition and formation of the specific Methamphetamine/Antibody/Methamphetamine complexes.

• Interpretation of results:

The appearance of only one line - C line, indicates a

Positive result, and that the methamphetamine level is at
a cutoff level or higher. And, the appearance of two lines –
both C line and T line indicates a negative result.

Discussion and Conclusion

- The results of the accuracy studies indicate that the correlation between the Instant-View™ Methamphetamine (Meth1000) Urine Test (Dip Strip) and the GC/MS is 97 %. Therefore the Instant-View™ Methamphetamine (Meth1000) Urine Test (Dip Strip) is substantially equivalent to the existing legally marketed product.
- The study results from clinical lab and the three physician's offices lab conducted by personals with diverse educational backgrounds and working experience agreed 100%, indicating that the Instant-View™ Methamphetamine (Meth1000) Urine Test (Dip Strip) is suitable for use by health care professionals with diverse educational backgrounds and work experience.



MAY 2 9 2001

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Naishu Wang, MD, Ph.D. President Alfa Scientific Designs, Inc. 11494 Sorrento Valley Road Suite M San Diego, CA 92121

Re:

510(k) Number: K003845

Trade/Device Name: Instant-ViewTM Methamphetamine (Meth 1000)

Urine Test (Dip Strip)

Regulation Number: 862.3610

Regulatory Class: II Product Code: LAF

Dated: November 21, 2000 Received: December 12, 2000

Dear Dr. Wang:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven I. Gutman, M.D., M.B.A.

Director

Division of Clinical Laboratory Devices

Steven Butman

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Page <u>1</u> of <u>1</u>
510(K) NUMBER (IF KNOWN): 1603845
DEVICE NAME: Instant-View™ Methamphetamine (Meth1000) Urine Test (Dip Strip)
INDICATIONS FOR USE:
It is for health care professional, in-vitro diagnostic use only.
This test is a qualitative one step lateral flow immunoassay intended for use in drug rehabilitation clinics, physician offices and reference labs. It provides qualitative screening results for Methamphetamine in human urine at a cutoff concentration of 1000ng/ml.
This assay provides only a preliminary result. Clinical consideration and professional judgment must be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. In order to obtain a confirmed analytical result, amore specific alternate chemical method is needed. Gas Chromatography/Mass Spectroscopy (GC/MS) is the preferred confirmation method.
(Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number K003845
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.)
Concurrence of CDRH, Office of Device Evaluation (ODE)

OR

Prescription Use

(Per 21 CFR 801.109)

Over-The-Counter Use____

(Optional Format 1-2-96)